Enriquez VA, Hernández CC, Carrillo RSC, Esponda PJG

Language: Spanish
References: 21
Page: 127-129
PDF size: 156.37 Kb.

ABSTRACT

Introduction: The use of immunoglobulins as adjunctive therapy in septic shock becomes a therapeutic option as an immunomodulator, and as a blocking mechanism of apoptosis.
Method: We reviewed retrospectively, patient’s charts with the diagnosis of septic shock on admission to the ICU, from August 1, 2014 to July 31, 2015. Two groups were formed, one with immunoglobulin as an adjuvant. We sought to measure the statistical survival through Kaplan-Meier analysis comparing its significance with Mantel-Cox.
Results: The cohort was formed of 18 patients diagnosed with septic shock. Both groups were formed with 9 patients each. Group 1 (immunoglobulin): had a mortality of 22% with a median of survival of 15 days compared to the Group 2 (no immunoglobulin): mortality of 55% with a median of 8 days, with a statistically significant difference (p = 0.004).
Conclusions: Our study showed that there was an increase in survival in patients receiving immunoglobulin compared to those without it. However, we believe that more prospective randomized trials should be made to recommend its use.

REFERENCES

1. Loza-Vázquez A, León-Gil C, León-Regidor A. Nuevas alternativas terapéuticas para la sepsis grave en el paciente crítico. Med Intensiva. 2011;35(4):236-245.

2. Conlledo R, Rodríguez A, Godoy J, Merino C, Martínez F. Globulinas totales y recuento linfocitario como marcadores de mortalidad en sepsis y shock séptico. Rev Chilena Infectol. 2012;29(2):192-199.

3. Mogica-Martínez MD. Uso terapéutico actual de la inmunoglobulina intravenosa. Rev Med Inst Mex Seguro Soc. 2006;44(Supl 2):81-86.

4. Berrón R, Espinosa F, Márquez MP, Sainos A, Marfil J, Selva J, et al. Consenso de expertos en el uso terapéutico actual de la inmunoglobulina intravenosa. Rev Alerg Mex. 2005;52(1):42-50.

5. Salinas J, Fica A. Inmunoglobulinas en sepsis y shock séptico. Rev Chil Infectol. 2005;22(1):21-31.

6. Montoya GCJ, Sorensen RU. Lecciones sobre el uso de gamaglobulina humana endovenosa. Boletín LAGID. 2001(23):971-1010.

7. Ozcan PE, Senturk E, Orhun G, Gumru S, Arican N, Orhan N, et al. Effects of intravenous immunoglobulin therapy on behavior deficits and functions in sepsis model. Ann Intensive Care. 2015;5(1):62.

8. Esen F, Senturk E, Ozcan PE, Ahishali B, Arican N, Orhan N, et al. Intravenous immunoglobulins prevent the breakdown of the blood-brain barrier inexperimentally induced sepsis. Crit Care Med. 2012;40(4):1214-1220.

9. Capasso L, Borrelli AC, Parrella C, Lama S, Ferrara T, Coppola C, et al. Are IgM-enriched immunoglobulins an effective adjuvant in septic VLBW infants? Ital J Pediatr. 2013;39:63.

10. Vincent JL. Emerging therapies for the treatment of sepsis. Curr Opin Anaesthesiol. 2015;28(4):411-416.

11. Nakamura K, Doi K, Okamoto K, Arai S, Ueha S, Matsushima K, et al. Specific antibody in IV immunoglobulin for postsplenectomy sepsis. Crit Care Med. 2013;41(8):e163-e170.

12. Toth I, Mikor A, Leiner T, Molnar Z, Bogar L, Szakmany T. Effects of IgM-enriched immunoglobulin therapy in septic-shock-induced multiple organ failure: pilot study. J Anesth. 2013;27(4):618-622.

13. Soares MO, Welton NJ, Harrison DA, Peura P, Shankar-Hari M, Harvey SE, et al. An evaluation of the feasibility, cost and value of information of a multicentre randomized controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess. 2012;16(7):1-186.

14. Esen F, Tugrul S. IgM-enriched Immunoglobulins in sepsis. (Chapter) In: Vincent JL, editor. Intensive Care Medicine Annual Update. New York: Springer-Verlag; 2009. pp. 102-110.

15. Di Rosa R, Pietrosanti M, Luzi G, Salemi S, D’Amelio R. Polyclonal intravenous immunoglobulin: an important additional strategy in sepsis? Eur J Intern Med. 2014;25(6):511-516.

16. Welte T, Dellinger RP, Ebelt H, Ferrer M, Opal SM, Schliephake DE, et al. Concept for a study design in patients with severe community-acquired pneumonia: a randomized controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study. Respir Med. 2015;109(6):758-767.

17. Almansa R, Tamayo E, Andaluz-Ojeda D, Nogales L, Blanco J, Eiros JM, et al. The original sins of clinical trials with intravenous immunoglobulins in sepsis. Crit Care. 2015;19:90.

18. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165-228.

19. Moreno R, Vincent JL, Matos R, Mendonça A, Cantraine F, Thijs L, et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med. 1999;25(7):686-696.

20. Metnitz PG, Moreno RP, Almeida E, Jordan B, Bauer P, Campos RA, et al. From evaluation of the patient to evaluation of the intensive care unit. Part 1: objectives, methods and cohort description. Intensive Care Med. 2005;31(10):1336-1344.

21. Metnitz PG, Moreno RP, Almeida E, Jordan B, Bauer P, Campos RA, et al. SAPS 3-From evaluation of the patient to evaluation of the intensive care unit. Part 2: development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med. 2005;31(10):1345-1355.